Clinical Trial Detail

NCT ID NCT02053636
Title A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements no
Sponsors Servier
Indications

breast adenocarcinoma

Therapies

Lucitanib

Age Groups: adult

No variant requirements are available.